Medimmune Limited

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Xing Cheng

Hong Jin

Kanta Subbarao

Matthew John McCourt

Danielle Carroll

Mark Galinski

Hyun Jung Park

Matthew Mccourt

The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy.

Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia

Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.

Influenza hemagglutinin and neuraminidase variants

The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described.

Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320

Growing community of inventors

Sunnyvale, CA, United States of America

Xing Cheng